CHARM Therapeutics Strengthens Leadership Team with Key Appointments to Support Drug Discovery and Development Capability
Retrieved on:
Wednesday, January 4, 2023
Biomedicine, Hoffmann-La Roche, Khosla Ventures, Stanford University, D, Machine learning, Roivant Sciences, Agios Pharmaceuticals, Pfizer, Doctor of Philosophy, Drug discovery, Head, Research, General Catalyst, Publication, Biology, Master of Science, Medicine, The Tumor, University of Minnesota College of Food, Agricultural and Natural Resource Sciences, Intelligence, AMAG Pharmaceuticals, ARIAD Pharmaceuticals, 3D, Therapy, Drug development, Vertex, Deep learning, GSK, Toxicology, University, Family, Cancer Research UK, Cell, Senior, Weill Cornell Graduate School of Medical Sciences, Pharmacokinetics, Merck & Co., MBA, Data management, Moscow State University, Immersion, DPU, Medical device, Pharmaceutical industry, Management, Crystallography, Science, Health care, Economics, Pharmacology, AI, Nature
LONDON – 4 January 2023 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research Company discovering and developing transformational medicines, today announces the expansion of its leadership team with a series of key appointments to strengthen its drug discovery and development, as well as operational management capabilities.
Key Points:
- Enhanced leadership team brings strong AI and drug discovery expertise and experience, reinforcing CHARM Therapeutics’ existing R&D capabilities
LONDON – 4 January 2023 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research Company discovering and developing transformational medicines, today announces the expansion of its leadership team with a series of key appointments to strengthen its drug discovery and development, as well as operational management capabilities. - These appointments will support CHARM as it builds out of its research and development function to advance discoveries driven by its proprietary 3D deep-learning engine towards development.
- CHARM Therapeutics raised $50 million in a Series A financing round announced in 2022, led by F-Prime Capital and OrbiMed, with General Catalyst and Khosla Ventures.
- Gary D. Glick Ph.D., Executive Chair of CHARM Therapeutics, commented: “The exceptional people joining CHARM bring the perfect combination of skills, from immersion in AI, oncology and translational research to long experience in organizational leadership.